MARKET COMPOSITE
CLRB - Cellectar Biosciences Inc8:00:00 PM 3/28/2024
Price
$3.98
+ 0.35 (9.49%)
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024 Cellectar Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today’s call is being recorded. Before […]

    Q4 2023 Cellectar Biosciences Inc Earnings Call

    Management to host a conference call today at 8:30 am ETFLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update. “2023 was a year of significant progress for Cellectar, culminating in the January announceme

    FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30

    FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details

    Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free Survival at One Year FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that iopofosine I 131 i

    FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation ar

    Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health’s National Cancer Institute (NCI)FLORHAM PARK, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the first patient has been enrolled in its Phase 1b clinical trial evaluating iopofosine I 131, a novel phospholi

    FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Tranche A warrants issued as part of the private placement announced in September 2023 have been exercised in full. All participants in the previous financing, led by Rosalind Advisors, exercised their warrants with gross proceeds

    Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS MalignanciesFLORHAM PARK, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that its novel phospholipid radiotherapeuti